VANCOUVER, British Columbia–(BUSINESS WIRE)–Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical
company developing multifunctional biotherapeutics, today announced that
management will present at the upcoming Raymond James Life Sciences and
MedTech Conference taking place June 18-19, 2019 in New York, NY.
The Company’s presentation will be on Wednesday, June 19, 2019 at 11:30
About Zymeworks Inc.
Zymeworks is a clinical-stage biopharmaceutical company dedicated to the
development of next-generation multifunctional biotherapeutics. The
Company’s suite of therapeutic platforms and its fully integrated drug
development engine enable precise engineering of highly
differentiated product candidates. Zymeworks’ lead clinical candidate,
ZW25, is a novel Azymetric™ bispecific antibody currently in Phase 2
clinical development. The Company’s second clinical candidate, ZW49, is
a bispecific antibody-drug conjugate currently in Phase 1 clinical
development and combines the unique design and antibody framework of
ZW25 with Zymeworks’ proprietary ZymeLink™ cytotoxic payload. Zymeworks
is also advancing a deep preclinical pipeline in immuno-oncology and
other therapeutic areas. In addition, its therapeutic platforms are
being leveraged through strategic partnerships with nine
biopharmaceutical companies. For more information, visit www.zymeworks.com.
Ryan Dercho, Ph.D.